✦ LIBER ✦

Randomized controlled trial of lymphoblastoid interferon α for chronic hepatitis C (comparison of 9-MU and 6-MU doses)

✍ Scribed by Kentaro Yoshioka; Motoyoshi Yano; Atsuhiko Kusakabe; Hideo Hirofuji; Akihiko Fuji; Junsuke Kuriki; Motohiro Arao; Kenichi Murase; Ryuichi Kidokoro; Shinichi Kakumu

Book ID: 119395956
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 39 KB
Volume: 94
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(98)00670-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High doses of recombinant α-interferon o

High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: A randomized, controlled trial

✍ Federico Sáez-royuela; Juan Carlos Porres; Alberto Moreno; Inmaculada Castillo; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant a-interferon or y-interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten

Prolonged treatment (2 years) with diffe

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C: Results of a multicenter randomized trial

✍ Giorgio Saracco; Elisabetta Borghesio; Pietro Mesina; Antonello Solinas; Claudia 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 852 KB

A randomized controlled trial of lymphob

A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg

✍ Giovanna Fattovich; Patrizia Farci; Massimo Rugge; Lucio Brollo; Antonella Manda 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoi

Efficacy of 5 MU of interferon in combin

Efficacy of 5 MU of interferon in combination with ribavirin for naı̈ve patients with chronic hepatitis C virus: a randomized controlled trial

✍ Alessandra Mangia; Maria Rosaria Villani; Nicola Minerva; Gioacchino Leandro; Do 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Comparative Effects of Different Doses o

Comparative Effects of Different Doses of Ribavirin Plus Interferon-α2b for Therapy of Chronic Hepatitis C: Results of a Controlled, Randomized Trial

✍ Herbert L. Bonkovsky; Denise Stefancyk; Kristina McNeal; Barbara F. Banner; Qin 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 103 KB

Interferon-α and zidovudine combination

Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial

✍ Harry L. A. Janssen; Luuk Berk; Rudolf A. Heijtink; Fiebo J. W. Ten Kate; Solko 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Interferon-a therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon-a and zidovudine in a subset of patients with presumably low response rates for interferon-a mon